These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 29146683

  • 1. PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS).
    Mefford MT, Rosenson RS, Cushman M, Farkouh ME, McClure LA, Wadley VG, Irvin MR, Bittner V, Safford MM, Somaratne R, Monda KL, Muntner P, Levitan EB.
    Circulation; 2018 Mar 20; 137(12):1260-1269. PubMed ID: 29146683
    [Abstract] [Full Text] [Related]

  • 2. PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort.
    Mitchell KA, Moore JX, Rosenson RS, Irvin R, Guirgis FW, Shapiro N, Safford M, Wang HE.
    PLoS One; 2019 Mar 20; 14(2):e0210808. PubMed ID: 30726226
    [Abstract] [Full Text] [Related]

  • 3. PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites.
    Kent ST, Rosenson RS, Avery CL, Chen YI, Correa A, Cummings SR, Cupples LA, Cushman M, Evans DS, Gudnason V, Harris TB, Howard G, Irvin MR, Judd SE, Jukema JW, Lange L, Levitan EB, Li X, Liu Y, Post WS, Postmus I, Psaty BM, Rotter JI, Safford MM, Sitlani CM, Smith AV, Stewart JD, Trompet S, Sun F, Vasan RS, Woolley JM, Whitsel EA, Wiggins KL, Wilson JG, Muntner P.
    Circ Cardiovasc Genet; 2017 Aug 20; 10(4):e001632. PubMed ID: 28768753
    [Abstract] [Full Text] [Related]

  • 4. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.
    Langsted A, Nordestgaard BG, Benn M, Tybjærg-Hansen A, Kamstrup PR.
    J Clin Endocrinol Metab; 2016 Sep 20; 101(9):3281-7. PubMed ID: 27218270
    [Abstract] [Full Text] [Related]

  • 5. PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations.
    Holmes MV, Kartsonaki C, Boxall R, Lin K, Reeve N, Yu C, Lv J, Bennett DA, Hill MR, Yang L, Chen Y, Du H, Turnbull I, Collins R, Clarke RJ, Tobin MD, Li L, Millwood IY, Chen Z, Walters RG, China Kadoorie Biobank Collaborative Group .
    Eur J Prev Cardiol; 2024 Jun 03; 31(8):1015-1025. PubMed ID: 38198221
    [Abstract] [Full Text] [Related]

  • 6. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
    Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybjærg-Hansen A.
    BMJ; 2017 Apr 24; 357():j1648. PubMed ID: 28438747
    [Abstract] [Full Text] [Related]

  • 7. PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults.
    Mefford MT, Marcovina SM, Bittner V, Cushman M, Brown TM, Farkouh ME, Tsimikas S, Monda KL, López JAG, Muntner P, Rosenson RS.
    J Lipid Res; 2019 Nov 24; 60(11):1946-1952. PubMed ID: 31511398
    [Abstract] [Full Text] [Related]

  • 8. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
    Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, Voros S, Giugliano RP, Davey Smith G, Fazio S, Sabatine MS.
    N Engl J Med; 2016 Dec 01; 375(22):2144-2153. PubMed ID: 27959767
    [Abstract] [Full Text] [Related]

  • 9. Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors.
    Khan AR, Bavishi C, Riaz H, Farid TA, Khan S, Atlas M, Hirsch G, Ikram S, Bolli R.
    Circ Cardiovasc Qual Outcomes; 2017 Jan 01; 10(1):. PubMed ID: 28073851
    [Abstract] [Full Text] [Related]

  • 10. The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy.
    Feng Q, Wei WQ, Chung CP, Levinson RT, Bastarache L, Denny JC, Stein CM.
    Pharmacogenomics J; 2017 Mar 01; 17(2):204-208. PubMed ID: 26902539
    [Abstract] [Full Text] [Related]

  • 11. The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.
    Ooi TC, Krysa JA, Chaker S, Abujrad H, Mayne J, Henry K, Cousins M, Raymond A, Favreau C, Taljaard M, Chrétien M, Mbikay M, Proctor SD, Vine DF.
    J Clin Endocrinol Metab; 2017 Sep 01; 102(9):3452-3460. PubMed ID: 28673045
    [Abstract] [Full Text] [Related]

  • 12. Sequence variation in proprotein convertase subtilisin/kexin type 9 serine protease gene, low LDL cholesterol, and cancer incidence.
    Folsom AR, Peacock JM, Boerwinkle E.
    Cancer Epidemiol Biomarkers Prev; 2007 Nov 01; 16(11):2455-8. PubMed ID: 18006936
    [Abstract] [Full Text] [Related]

  • 13. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P, Ganz P, Ma Y, Scherzer R, Hur S, Weigel B, Grunfeld C, Deeks S, Wasserman S, Scott R, Hsue PY.
    J Am Heart Assoc; 2016 Apr 29; 5(5):. PubMed ID: 27130349
    [Abstract] [Full Text] [Related]

  • 14. Letter by Koh Regarding Article, "PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS)".
    Koh KK.
    Circulation; 2018 Sep 18; 138(12):1283-1284. PubMed ID: 30354438
    [No Abstract] [Full Text] [Related]

  • 15. Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease.
    Dron JS, Patel AP, Zhang Y, Jurgens SJ, Maamari DJ, Wang M, Boerwinkle E, Morrison AC, de Vries PS, Fornage M, Hou L, Lloyd-Jones DM, Psaty BM, Tracy RP, Bis JC, Vasan RS, Levy D, Heard-Costa N, Rich SS, Guo X, Taylor KD, Gibbs RA, Rotter JI, Willer CJ, Oelsner EC, Moran AE, Peloso GM, Natarajan P, Khera AV.
    JAMA Cardiol; 2023 Mar 01; 8(3):258-267. PubMed ID: 36723951
    [Abstract] [Full Text] [Related]

  • 16. PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials.
    Swiger KJ, Martin SS.
    Drug Saf; 2015 Jun 01; 38(6):519-26. PubMed ID: 25989944
    [Abstract] [Full Text] [Related]

  • 17. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
    Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS.
    Circulation; 2018 Jan 23; 137(4):338-350. PubMed ID: 29133605
    [Abstract] [Full Text] [Related]

  • 18. Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study.
    Cupido AJ, Reeskamp LF, Hingorani AD, Finan C, Asselbergs FW, Hovingh GK, Schmidt AF.
    JAMA Cardiol; 2022 Sep 01; 7(9):955-964. PubMed ID: 35921096
    [Abstract] [Full Text] [Related]

  • 19. Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.
    Hopewell JC, Malik R, Valdés-Márquez E, Worrall BB, Collins R, METASTROKE Collaboration of the ISGC.
    Eur Heart J; 2018 Feb 01; 39(5):354-359. PubMed ID: 29020353
    [Abstract] [Full Text] [Related]

  • 20. Trajectory of Cognitive Decline After Incident Stroke.
    Levine DA, Galecki AT, Langa KM, Unverzagt FW, Kabeto MU, Giordani B, Wadley VG.
    JAMA; 2015 Jul 07; 314(1):41-51. PubMed ID: 26151265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.